

**Drug Utilization Review Board  
Minutes Draft**

**Name of Meeting:** Drug Utilization Review Board  
**Date of Meeting:** August 21, 2014  
**Length of Meeting:** 1 hour and 34 minutes  
**Location of Meeting:** DMAS Board Room 13<sup>th</sup> Floor

**Members Present:**

Randy Ferrance, MD, Chair  
Avtar Dhillon, MD  
Seth Brant, MD  
Bill Rock, PharmD

Jane Settle, NP, Vice Chair  
Wendy Nash, PharmD  
Jamie Haight, RPh  
Cynthia Fagan, FNP

**Members Not Present:**

Rhonda Bass, MD  
Michelle Thomas, PharmD  
Sandra Dawson, RPh  
Jonathan Evans, MD

**DMAS Attendees:**

Rachel Cain, PharmD  
Donna Proffitt, RPh  
Bryan Tomlinson  
Danielle Adeeb  
Tyrone Wall  
Kim Richardson

**Contractors:**

Donna Johnson, PharmD, Clinical Pharmacy Manager, Xerox  
Tina Carter, CPhT, Pharmacy Technician, Xerox

**Vendors:**

Debbie Moody, RPh, Magellan Health Services

**Visitors:**

Denise Gomes, VCU Medical Center  
Lindsay Berry, Anthem  
Mark Kenny, Astra Zeneca  
Judy Buchanan, Gilead  
Pat Cannon, Novartis  
John Scott, Novo Nordisk  
Michelle Jacobs, Otsuka  
Kevin Howard, Pfizer  
Gerard Vandermeys, Sunovion  
Kathryn Mathias, Takeda

Jason Richardson, Actavis  
Andre' Melvin, Astellas Pharma U.S  
Christina Fung, Genentech  
Emily Holmes, KB  
Erik Hecht, Novo Nordisk  
Patti Denman, Novo Nordisk  
Rod Teat, Otsuka  
Alex Kuss, Sunovion  
Ralston King, Sunovion

## **Call to Order and Introductions**

Dr. Ferrance called the meeting to order at 2:02pm.

## **Minutes—May 22, 2014**

Dr. Ferrance asked if there were any additions or deletions to the minutes from the May 22, 2014 meeting. Dr. Nash stated that she made a motion and not a recommendation, on page three under Future Topics, for the Board to consider preventive care solutions such as promoting utilization of the influenza vaccine for the 2014-2015 flu season by sending letters to prescribers. She has requested this correction upon review of the recorded meeting. Dr. Johnson stated that the necessary changes to the meeting minutes will be made upon review of the recorded meeting. The motion was made and seconded for the meeting minutes to be approved with stated revisions. The Board voted unanimously to approve the minutes.

After review of the recorded May 2014 meeting, the revision to the minutes will state as follows:

Additional topics were suggested by the Board. Dr. Nash made the motion that the Board consider preventive care solutions such as promoting utilization of the influenza vaccine for the 2014-2015 flu season by sending letters to prescribers. The Board seconded the motion. However, upon further discussion it was determined that since many patients obtain their influenza vaccines without a prescription at local pharmacies, it would be very difficult to associate the patient with a prescriber thus making targeted interventions impossible.

## **New Drugs**

**Jublia® (efinaconazole)** – Dr. Johnson presented DUR and Service Authorization (SA) criteria. The motion was made to accept the criteria as written with the following editorial changes to the SA criteria. The criteria will be modified so that the requirement of a trial of an oral antifungal will be waived if there was a failure on oral antifungal therapy **OR** the patient has an allergy or contraindication to an oral antifungal then step to a trial of the generic ciclopirox topical solution first before allowing a brand name topical onychomycosis agent. The Board seconded and approved the criteria.

**Sivextro® (tedizolid)** – Dr. Johnson presented the DUR and SA criteria. The motion was made to accept the DUR criteria as written with the addition of drug-drug interactions with MAOIs and SSRIs (Sev 2). The motion was made to accept the SA criteria with the addition of “resistant” to an alternative first line antibiotic and changing the culture and sensitivity requirement from “sensitive to Sivextro” to “sensitive to oxazolidinones”.

Dr. Johnson also presented SA criteria for Zyvox® (linezolid). The motion was made to accept the criteria as written with the addition of “resistant to an alternative first line antibiotic” and changing the culture and sensitivity requirement from “sensitive to Zyvox” to “sensitive to oxazolidinones”. The Board seconded and approved the criteria.

**Tanzeum® (albiglutide)** – Dr. Johnson presented the DUR criteria. The motion was made to accept the criteria as written; the Board seconded and approved the criteria.

**Zontivity® (vorapaxar sulfate)** – Dr. Johnson presented the DUR criteria. The motion was made to accept the criteria as written; the Board seconded and approved the criteria.

**Zykadia® (ceritinib)** – Dr. Johnson presented the DUR and SA criteria. The motion was made to accept the criteria as written; the Board seconded and approved the criteria.

### **Service Authorizations**

**Synagis®** - Dr. Johnson reviewed the recently revised RSV guidelines by the American Academy of Pediatrics. She presented recommendations for changes to the current SA criteria. The Board approved the recommended changes based on current guidelines.

### **Reports**

**ProDUR and RetroDUR** –Dr. Johnson reviewed the reports provided in the DUR Board binder; there were no questions or comments.

**Utilization Analysis Reports** – Dr. Johnson reviewed the Top 25 Drugs Ranked by Claim Count, by Payment Amount and the Cost of Utilization Analysis by Drug Type. Dr. Cain noted the high volume of compound claims seen on the Top 25 Drugs by Payment report. Dr. Johnson suggested that further analysis be performed to determine the nature of the compounds and their ingredients.

**Top Diagnoses by Age** – Dr. Johnson reviewed the Top Diagnoses by Age for all ages; there were no questions or comments.

### **AAP Report**

Dr. Johnson reviewed the report provided in the DUR Board binder. She noted that this report includes children < 6 years old who are on an atypical antipsychotic. On July 1, 2014, DMAS expanded the program to include children on any antipsychotic under the age of 13 years of age. These changes will be reflected in the report at the next Board meeting.

### **High Cost Drugs**

Dr. Johnson reviewed an analysis of the utilization of all High Cost Drugs filled only once. The emphasis was on chemotherapy and HIV medications where therapy was not continued after the initial fill. The Board requested verification of continuous enrollment.

### **Future Topics**

Metabolic Monitoring in Patients on Atypical Antipsychotics  
Analysis of Compounded Medications to review ingredients  
Analysis to determine the incidence of bleeds in patients on dabigatran  
Analysis to determine the incidence of emergency department visits in patients on zolpidem

### **Other Business**

Dr. Ferrance spoke words of gratitude to Jane Settle, NP, Vice Chair for her 17 years of service to the DUR Board upon her retirement.

**Meeting was adjourned at 3:36 pm.**

**Next DUR Board Meeting scheduled for November 20, 2014.**